To the full analysis
Buyback calculator for Acadia Pharmaceuticals
Acadia Pharmaceuticals stock: key metrics
ACADAcadia Pharmaceuticals had an operating margin of 9.8% and a return on invested capital (ROIC) of 42.9% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 100.0% | −603.1% | −553.9% |
| 2007 | 100.0% | −829.3% | −746.4% |
| 2008 | 100.0% | −4,212.5% | −4,040.5% |
| 2009 | 100.0% | −710.5% | −705.5% |
| 2010 | 100.0% | 35.8% | 35.9% |
| 2011 | 100.0% | −1,105.6% | −1,101.4% |
| 2012 | −283.0% | −425.6% | −424.9% |
| 2013 | −2,233.8% | −3,344.7% | −3,314.2% |
| 2014 | −50,401.7% | −77,691.7% | −77,062.5% |
| 2015 | −125,095.1% | −269,855.7% | −269,578.7% |
| 2016 | 74.6% | −1,574.1% | −1,565.9% |
| 2017 | 89.5% | −234.1% | −231.7% |
| 2018 | 91.8% | −110.6% | −109.6% |
| 2019 | 94.2% | −72.7% | −69.4% |
| 2020 | 95.3% | −64.9% | −63.7% |
| 2021 | 96.0% | −35.2% | −34.7% |
| 2022 | 98.0% | −43.2% | −41.8% |
| 2023 | 93.7% | −10.1% | −8.4% |
| 2024 | 91.5% | 24.1% | 23.6% |
| 2025 | 91.7% | 9.8% | 36.5% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −67.1% | −55.4% | −50.3% |
| 2007 | −49.5% | −53.1% | −41.9% |
| 2008 | −100.0% | −62.0% | −99.3% |
| 2009 | −100.0% | −80.0% | −90.9% |
| 2010 | 51.0% | 44.5% | 39.4% |
| 2011 | −97.4% | −61.7% | −70.9% |
| 2012 | −24.5% | −25.7% | −19.2% |
| 2013 | −20.8% | −21.2% | −20.1% |
| 2014 | −29.9% | −30.0% | −28.4% |
| 2015 | −82.3% | −51.0% | −74.1% |
| 2016 | −52.4% | −60.0% | −48.4% |
| 2017 | −86.3% | −54.1% | −75.3% |
| 2018 | −51.2% | −47.9% | −45.4% |
| 2019 | −33.7% | −32.7% | −30.0% |
| 2020 | −44.9% | −32.5% | −36.0% |
| 2021 | −31.0% | −20.9% | −24.0% |
| 2022 | −53.9% | −33.1% | −36.7% |
| 2023 | −14.2% | −12.0% | −8.2% |
| 2024 | 30.9% | 31.2% | 19.1% |
| 2025 | 31.9% | 42.9% | 25.0% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Sep 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.